Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography for Image Guidance in Percutaneous Patent Foramen Ovale Closure

Jeonggeun Moon †, Yeonjeong Park †, Su Jung Park, Pyung Chun Oh, Albert Youngwoo Jang, Wook-Jin Chung and Woong Chol Kang *

Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon 21927, Korea; jeff76@gilhospital.com (J.M.); pyj0222@gilhospital.com (Y.P.); image4631@gilhospital.com (S.J.P.); likeymed@gilhospital.com (P.C.O.); cardio_gil@gilhospital.com (A.Y.J.); heart@gilhospital.com (W.J.C.)

* Correspondence: kangwch@gilhospital.com; Tel.: +82-32-460-3054 (ext. 8305); Fax: +82-32-469-1906
† These authors contributed equally to this work.

Received: 26 June 2020; Accepted: 5 August 2020; Published: 9 August 2020

Abstract: Background and Objectives: Transesophageal echocardiography (TEE) guidance is the current gold standard for catheter-based procedures in the treatment of structural heart diseases. Intracardiac echocardiography (ICE), which can be performed under local anesthesia, has been recently introduced and is becoming more widely used. We aimed to compare the efficacy and safety of ICE and TEE in patent foramen ovale (PFO) device closure. Materials and Methods: All 74 patients with a history of cryptogenic stroke undergoing PFO closure for secondary prophylaxis were selected from our registry. Intraprocedural TEE was performed by echocardiographer-cardiologists with the patient under general anesthesia. Conversely, ICE was performed with the patient under local anesthesia. Baseline characteristics, procedural details, and immediate outcomes were compared between the TEE and ICE groups (n = 49 and n = 25, respectively). Results: Although patients in the ICE group were older (47 ± 10 vs. 57 ± 7 years, p < 0.001), sex and comorbidity variables were similar between the two groups. The degree of inducible right-to-left shunt via the PFO, assessed using preprocedural TEE, was also comparable. Notably, fluoroscopy time (22 ± 18 vs. 16 ± 7 min, p = 0.030), radiation dose (498 ± 880 vs. 196 ± 111 mGy, p = 0.022), and total procedural time in the catheter laboratory (99 ± 30 vs. 67 ± 12 min, p < 0.001) were significantly lower in the ICE group than those in the TEE group. The entire hospital stay was similar between groups (3.8 ± 2.2 vs. 3.4 ± 1.3 days, p = 0.433). No procedural complications, such as device embolization, pericardial hemorrhage, major bleeding, mortality, or access-related vascular injury were reported in either group. Conclusions: ICE-guided PFO device closure is quicker and less hazardous in terms of radiation exposure than the TEE-guided procedure, with similar procedural outcomes and duration of hospital stay.

Keywords: patent foramen ovale; intracardiac echocardiography; transesophageal echocardiography.

1. Introduction

The foramen ovale is a physiological shunt of fetal circulation and normally fuses spontaneously after birth. However, the process of fusion fails in about a quarter of the general population, resulting in a patent foramen ovale (PFO) [1]. PFO is believed to be associated with cryptogenic stroke (CS) [2,3] because it could serve both as a nidus for in situ thrombus formation and a conduit of paradoxical embolism [4]. Patients with CS are usually young; hence, prevention of a recurrence is of paramount
importance. With the recent introduction of sealing devices and advances in interventional techniques, PFO device closure is being performed more frequently, and it has shown better long-term outcomes than medical therapy in select patients with a history of CS [5–7].

PFO device closure is usually performed under the guidance of real-time transesophageal echocardiography (TEE) with the assistance of echocardiographer-cardiologists. However, the main drawback of TEE-guided PFO device closure is the requirement of general anesthesia, which necessitates an anesthesia team. Alternatively, the recently introduced intracardiac echocardiography (ICE), which is usually performed by an interventional cardiologist, is being more widely used to guide the closure of interatrial communications because it is well tolerated by patients [8–10]. Although approximately half of the interatrial communication closures currently being performed are done under ICE guidance, no direct comparison has been reported between the conventional TEE-guided PFO closure and the newer ICE-guided procedure [8,9]. In this study, we aimed to compare the efficacy and safety of the two device closure procedures in patients with CS.

2. Materials and Methods

2.1. Study Population

This was a retrospective observational study using the PFO registry of the attending hospital. From March 2014 to September 2019, all 165 patients who had experienced a CS or recurrent transient ischemic attack (TIA) had a PFO documented using TEE, and underwent PFO device closure, were entered in the registry. Among them, 74 patients were identified as the study population.

CS was defined as a stroke with no identifiable cause after excluding carotid or intracranial artery stenosis, atrial fibrillation, intracardiac thrombus, and atheromatous plaque at the aortic arch [2]. PFO closure was determined according to the discretion of the heart team (consisting of an interventional cardiologist, an echocardiographer-cardiologist, a neurologist, and a radiologist) based on clinical data, echocardiographic findings, and patient preference. All patients (51 men, overall mean age 50 years) had a PFO of more than moderate grade, as assessed according to previous studies [11,12]. The Amplatzer® PFO Occluder (St. Jude Medical, St. Paul, MN, USA), GORE® Septal Occluder (WL Gore and Associates Inc., Newark, DE, USA), and Occlutech Figulla® PFO Occluder (Occlutech GmbH, Jena, Germany) were implanted in all patients. The current study conformed to the Declaration of Helsinki (sixth revision). The Institutional Review Board of Gil Medical Center, Gachon University College of Medicine approved this study (GDIRB 2014-35, 24 February 2014), and all patients provided written informed consent before enrollment.

2.2. Assessment of PFO Shunt Grade and Presence of an Atrial Septal Aneurysm (ASA)

PFO shunt size was assessed by using TEE-based agitated saline contrast study with the Valsalva maneuver. A shunt was defined as the appearance of contrast bubbles in the left atrium (LA) within three cardiac cycles of opacification of the right atrium (RA). Shunt degrees were defined as mild, moderate, and severe if 3–9, 10–30, and >30 contrast bubbles, respectively, appeared in the LA [11–13]. Shunt at rest was defined as the appearance of contrast bubbles in the LA within three cardiac cycles of RA opacification with normal respiration or presence of shunt flow on color Doppler [11,12]. ASA was defined as interatrial septal excursion of ≥10 mm from the midline during the cardiac cycle [14].

2.3. TEE Guided PFO Closure Procedure

The closure procedure was performed under general anesthesia. All procedures were performed by one operator (W.C.K.). One experienced echocardiographer-cardiologist (J.M.) performed TEE to help the operator make decisions during the procedure. After achieving femoral venous access, the PFO was crossed with a 5-Fr multipurpose catheter, which was advanced into the left upper pulmonary vein and exchanged over a 0.035-inch J-tipped stiff guidewire for an 8- or 9-Fr guiding sheath. Procedural anticoagulation was initiated with intravenous administration of 5000 units of
unfractionated heparin. Thereafter, additional heparin was administered throughout the procedure to maintain an activated clotting time of ≥250 s. The size of the device was based on the TEE measurements of the distance between the PFO and aortic root. Device implantation was performed using previously described methods [15]. TEE was used to facilitate the implantation of the device and to confirm its successful positioning.

2.4. ICE Guided PFO Closure Procedure

All ICE-guided PFO closure procedures were performed under local anesthesia without conscious sedation. All procedures were performed by one operator (W.C.K.). The right and left femoral veins were punctured to introduce an 8- or 9-Fr and 8.5-Fr sheaths for the PFO closure device and ICE catheter, respectively. The ICE catheter was positioned in the RA through the sheath and was maneuvered for optimal visualization of the PFO. The procedure did not differ from the TEE-guided one except that the device was deployed under the guidance of ICE images.

2.5. Postprocedural Management and Study Endpoint

The recommended anti-platelet therapy after the procedure included daily intake of both aspirin 100 mg and clopidogrel 75 mg for at least 6 months. Thereafter, further use of any blood thinners was left to the discretion of the attending physician. The Risk of Paradoxical Embolism (RoPE) scoring system—comprised of age, history of hypertension, diabetes mellitus, stroke/TIA, smoking status, and cortical infarct on imaging—was used to stratify patients with PFO and CS according to the probability that the latter was attributable to the former [16,17]. Continuous electrocardiogram monitoring was performed during the PFO closure, and a 12-lead electrocardiogram was obtained immediately, 12 h and 36 h after the index procedure. Procedural success was defined as a successful device implantation with no procedure-related complications or in-hospital or morbidity or mortality.

2.6. Statistical Analysis

Continuous data are presented as mean ± standard deviation. Discrete variables are presented as absolute value and percentage. Continuous variables were compared using a two-sample t-test, whereas categorical variables were compared using chi-square and Fisher’s exact tests. Analysis of primary endpoint longitudinal data was performed using Kaplan–Meier estimates with log-rank test. p-values of <0.05 were considered statistically significant. The analysis was performed using SPSS version 20 (SPSS Inc., Chicago, IL, USA).

3. Results

Baseline clinical and TEE characteristics are shown in Table 1. The number of patients was larger in the TEE group than that in the ICE group (49 vs. 25). ICE group patients were older and had a lower prevalence of dyslipidemia. The main indication for PFO was stroke rather than TIA. The RoPE score was lower in the ICE group. On preprocedural TEE, the degree of inducible right-to-left shunt via the PFO was similar between the two groups. Resting shunt and the presence of ASA, both considered components of high-risk PFO, were comparable between the two groups.
Table 1. Baseline clinical and transesophageal echocardiographic characteristics.

| Clinical Characteristics | TEE (n = 49) | ICE (n = 25) | p-Value * |
|--------------------------|-------------|-------------|-----------|
| Age, years               | 47 ± 10     | 57 ± 7      | <0.001    |
| Female sex, n            | 16 (33%)    | 7 (28%)     | 0.683     |
| Smoking, n               | 15 (31%)    | 11 (44%)    | 0.254     |
| Body mass index, kg/m²   | 24.9 ± 3.6  | 24.8 ± 3.2  | 0.943     |
| Comorbidities, n         |             |             |           |
| Hypertension             | 15 (31%)    | 11 (44%)    | 0.254     |
| Diabetes mellitus        | 7 (14%)     | 7 (28%)     | 0.154     |
| Dyslipidemia             | 19 (39%)    | 3 (12%)     | 0.017     |
| Coronary artery disease  | 1 (2%)      | 0 (0%)      | 0.472     |
| Peripheral artery disease| 1 (2%)      | 0 (0%)      | 0.472     |
| Myocardial infarction    | 0 (0%)      | 0 (0%)      | -         |
| Heart failure            | 0 (0%)      | 0 (0%)      | -         |
| Chronic obstructive pulmonary disease | 0 (0%) | 0 (0%) | - |
| Indication for PFO closure, n (%) | -  | - | - |
| Stroke                   | 41 (84%)    | 24 (96%)    | 0.125     |
| Recurrent TIA            | 8 (16%)     | 1 (4%)      | 0.125     |
| Cortical infarct on imaging | 32 (65%)    | 18 (72%)    | 0.073     |
| RoPE score               | 6.4 ± 1.7   | 5.5 ± 1.4   | 0.042     |

Preprocedural TEE Characteristics

| Degree of shunt at Valsalva maneuver, n (%) | - | - | 0.223 |
|---------------------------------------------|---|---|-------|
| Mild                                        | 12 (24%) | 4 (16%) | - |
| Moderate                                    | 18 (37%) | 6 (24%) | - |
| Severe                                      | 19 (39%) | 15 (60%) | - |
| Shunt at rest, n (%)                       | 8 (16%) | 4 (16%) | 0.971 |
| Atrial septal aneurysm, n (%)               | 0 (0%) | 1 (4%) | 0.159 |

* p < 0.05 was considered significant; TEE, transesophageal echocardiography; ICE, intracardiac echocardiography; PFO, patent foramen ovale; TIA, transient ischemic attack; RoPE, Risk of Paradoxical Embolism.

Figure 1 demonstrates a typical TEE-guided procedure. TEE renders not only a two-dimensional PFO image (A) but also a good-quality color Doppler image of the resting left-to-right shunt via the PFO (B). An echocardiographer-cardiologist discusses with the operator about device deployment (C) and the result of the PFO device closure (D) during the procedure. Figure 2 is a representative image of the ICE-guided procedure. ICE provides good images of the PFO inlet being pushed by a guiding catheter (A), passage of the catheter through the PFO (B), deployment of the PFO closure device (C), and good positioning of the device (D).
Figure 1. TEE-guided PFO device closure. A 40-year-old woman with a large PFO with resting left-to-right shunt underwent successful PFO device closure without any complication. TEE renders not only a two-dimensional PFO image (A) but also a good-quality color Doppler image of the resting left-to-right shunt via the PFO (B). An echocardiographer-cardiologist discusses with the operator about device deployment (C) and the result of the PFO device closure (D) during the procedure. TEE, transesophageal echocardiography; PFO, patent foramen ovale; RA, right atrium; LA, left atrium.
Figure 2. ICE-guided PFO device closure. The images were from a 68-year-old man who underwent successful PFO device closure without any complication. ICE provides good images of the PFO inlet being pushed by a guiding catheter (A), passage of the catheter through the PFO (B), deployment of the PFO closure device (C), and good positioning of the device (D). ICE, intracardiac echocardiography; PFO, patent foramen ovale; RA, right atrium; LA, left atrium.

Table 2 provides the procedural and periprocedural details. Notably, fluoroscopy time and radiation dose were significantly lower in the ICE group than those in the TEE group. Total time in the catheterization laboratory was also notably shorter in the ICE group, and the same was true for the time from the venous puncture to vascular closure, time from arrival at the catheterization laboratory to venous puncture, and time from vascular closure until exiting the catheterization laboratory (p < 0.05 for all). The length of hospital stay did not differ between the TEE and ICE groups. No procedural complications were reported in both groups.
Table 2. Procedural and periprocedural details.

|                                | TEE (n = 49) | ICE (n = 25) | p-Value * |
|--------------------------------|--------------|--------------|-----------|
| Implanted device, n (%)       |              |              | <0.001    |
| Gore Septal Occluder          | 20 (41%)     | 0 (0%)       | -         |
| Amplatzer PFO Occluder        | 17 (35%)     | 0 (0%)       | -         |
| Occlutech PFO Occluder        | 12 (24%)     | 25 (100%)    | -         |
| Device size, n (%)            |              |              | 0.162     |
| 18 mm                         | 5 (10%)      | 0 (0%)       | -         |
| 25 mm                         | 37 (76%)     | 23 (92%)     | -         |
| 30 mm                         | 7 (14%)      | 2 (8%)       | -         |
| Fluoroscopy time, min         | 22 ± 18      | 16 ± 7       | 0.030     |
| Radiation dosage, mGy         | 498 ± 880    | 196 ± 111    | 0.022     |
| Total time in cath. lab., min | 99 ± 30      | 67 ± 12      | <0.001    |
| From venous puncture until vascular closure | 53 ± 29 | 43 ± 11 | 0.020 |
| From arrival at cath. lab. until venous puncture | 23 ± 10 | 13 ± 4 | <0.001 |
| From vascular closure until exiting the cath. lab. | 23 ± 8 | 11 ± 3 | <0.001 |
| Length of stay, days          | 3.8 ± 2.2    | 3.4 ± 1.6    | 0.433     |
| Complication, n (%)           |              |              | -         |
| Atrial fibrillation           | 0 (0%)       | 0 (0%)       | -         |
| Device embolization           | 0 (0%)       | 0 (0%)       | -         |
| Pericardial effusion with tamponade | 0 (0%) | 0 (0%) | - |
| Major bleeding                | 0 (0%)       | 0 (0%)       | -         |
| Death                         | 0 (0%)       | 0 (0%)       | -         |
| Access-related complications  | 0 (0%)       | 0 (0%)       | -         |

* p < 0.05 was considered significant; TEE, transesophageal echocardiography; ICE, intracardiac echocardiography; PFO, patent foramen ovale; cath. lab., catheterization laboratory.

4. Discussion

The number of cases of PFO device closure for secondary prophylaxis of CS has been consistently increasing since its introduction in the late 1980s [18]. Most of the interventional procedures are performed with imaging guidance using TEE, which has been the modality of choice, or ICE, which was more recently introduced and is being increasingly used [19]. Although TEE is the diagnostic test of choice for preprocedural assessment of a PFO to define the anatomy of the atrial septum and its surrounding structures, intraprocedural TEE requires deep sedation, which is the main shortcoming of the semi-invasive imaging tool. Meanwhile, the strengths of the more recently introduced ICE include the following: (1) as patients normally tolerate ICE well, general anesthesia is scarcely needed; (2) ICE provides good image quality; and (3) ICE is performed by interventional cardiologists themselves [10]. Therefore, ICE-based PFO closure is expected to be superior to the TEE-guided procedure in terms of procedural time and logistics. In addition, ICE reduces the radiation hazard to both patients and interventionists by decreasing fluoroscopy time, and may improve outcomes in interventional procedures for treating arrhythmia [20,21] or structural heart disease [9,22]. In this study, we compared the procedural efficacy and safety of TEE-guided and ICE-guided PFO device closure and found equal procedural outcomes. Of note, as clearly proved in this study, using ICE in PFO device closure remarkably shortens the procedural time. ICE-guided procedure also lowers the requirement for fluoroscopic assessment during the intervention compared with TEE-guided procedure. To the best of our knowledge, this is the first study to directly compare TEE and ICE as guiding tools for PFO device closure.

The feasibility of ICE to guide device closure for interatrial septal communication has been established [10,19,23,24]. However, ICE is not yet universally used in PFO device closure. The reasons for this include relative lack of experience of interventional cardiologists and the concern about potential complications such as vascular injury of femoral access site, cardiac perforation resulting in tamponade, and arrhythmia resulting from intracardiac stimulation by ICE probe navigation. Nevertheless, Alqahtani et al. [19] reported that ICE did not increase procedure-related complications
when compared with TEE in guiding interatrial communication closure. The current study also demonstrated the safety of ICE-guided PFO closure in that no major complications were observed in both patient groups, which suggests that PFO device closure is essentially safe when performed in an experienced center. Another strength of the ICE-guided procedure is provision of a better image of the fossa ovalis and septum primum/secundum with the probe in the RA very close to the PFO (Figure 2). Thus, ICE allows for guiding and monitoring of the entire procedure by the operator himself/herself and provides better images of the atrial septal anatomy, catheter movement, and device deployment than TEE (Figures 1 and 2).

Although ICE-guided PFO closure is safe and effective, another issue that needs to be considered is the validation of ICE images. Vigna et al. [25] reported a significant disagreement in the anatomical evaluation of the PFO between preprocedural TEE and intraprocedural ICE images, although the clinical implications of this remain unclear. However, it needs to be taken into consideration, especially among patients with complex anatomic variations of the fossa ovalis, such as in ASA, because the preprocedural evaluation of PFO is normally performed with TEE rather than ICE.

This study has all the inherent limitations of non-randomized single-center studies. The patient numbers and demographic features were not equal between the TEE and ICE groups. In addition, the sample size was small; hence, the difference in numbers between the two groups was not adjusted for. The use of closure devices from different manufacturers were not evenly distributed in the TEE- and ICE-group for technical issues and might be a confounder. Our institution is a tertiary referral medical center; hence, the current study patients may not be representative of all CS patients undergoing PFO device closure for secondary prevention. Notably, we enrolled consecutive patients, and the main operator in all procedures was identical (W.C.K, who has performed PFO-device closure in 165 patients over 6 years as of January 2020); therefore, the procedural learning curve favors a shorter procedural time in the ICE group because ICE was introduced later (June 2018) than TEE at our center. Atrial arrhythmia, including atrial premature complex, sustained-/non-sustained atrial tachycardia, or atrial fibrillation, occurs occasionally during PFO-device closure. Although no atrial fibrillation was detected in the current cohort, we do not have data of procedure-related transient cardiac rhythm disorder, so they were omitted from analysis.

5. Conclusions

ICE-guided PFO device closure is quicker and less hazardous in terms of radiation exposure than the TEE-guided procedure, with similar procedural outcomes and hospital stay duration. As such, ICE is a promising imaging modality for its safety and efficacy, and it would be more widely used to guide the PFO closure. However, the discrepancy between preprocedural TEE and intraprocedural ICE images requires validation.

Author Contributions: Conceptualization, W.C.K. and J.M.; methodology, P.C.O.; software, J.M.; validation, W.-J.C. and W.C.K.; formal analysis, Y.P.; investigation, Y.P.; resources, S.J.P.; data curation, A.Y.J.; writing—original draft preparation, J.M.; writing—review and editing, Y.J.P.; visualization, J.M.; supervision, W.C.K.; project administration, W.C.K.; funding acquisition, W.C.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant No.: HI16C2319).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Hagen, P.T.; Scholz, D.G.; Edwards, W.D. Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin. Proc. 1984, 59, 17–20. [CrossRef]
2. Alsheikh-Ali, A.A.; Thaler, D.E.; Kent, D.M. Patent foramen ovale in cryptogenic stroke: Incidental or pathogenic? Stroke 2009, 40, 2349–2355. [CrossRef] [PubMed]
3. Khairy, P.; O'Donnell, C.P.; Landzberg, M.J. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: A systematic review. *Ann. Intern. Med.* 2003, 139, 753–760. [CrossRef] [PubMed]

4. Kizer, J.R.; Devereux, R.B. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. *N. Engl. J. Med.* 2005, 353, 2361–2372. [CrossRef] [PubMed]

5. Saver, J.L.; Carroll, J.D.; Thaler, D.E.; Smalling, R.W.; MacDonald, L.A.; Marks, D.S.; Tirschwell, D.L.; Investigators, R. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. *N. Engl. J. Med.* 2017, 377, 1022–1032. [CrossRef]

6. Mas, J.L.; Derumeaux, G.; Guillon, B.; Massardier, E.; Hosseini, H.; Mechtilouff, L.; Arquizaan, C.; Bejot, Y.; Vuillier, F.; Detante, O.; et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplateletst after Stroke. *N. Engl. J. Med.* 2017, 377, 1011–1021. [CrossRef] [PubMed]

7. Sondergaard, L.; Kasner, S.E.; Rhodes, J.F.; Andersen, G.; Iversen, H.K.; Nielsen-Kudsk, J.E.; Settergren, M.; Sjostrand, C.; Roine, R.O.; Hildick-Smith, D.; et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. *N. Engl. J. Med.* 2017, 377, 1033–1042. [CrossRef]

8. Boccalandro, F.; Baptista, E.; Muench, A.; Carter, C.; Smalling, R.W. Comparison of intracardiac echocardiography versus transesophageal echocardiography guidance for percutaneous transcatheter closure of atrial septal defect. *Am. J. Cardiol.* 2004, 93, 437–440. [CrossRef]

9. Bartel, T.; Konorza, T.; Arjumand, J.; Ebradlidze, T.; Eggebrecht, H.; Caspari, G.; Neudorf, U.; Erbel, R. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. *Circulation* 2003, 107, 795–797. [CrossRef]

10. Enriquez, A.; Saenz, L.C.; Rosso, R.; Silvestry, F.E.; Callans, D.; Marchlinski, F.E.; Garcia, F. Use of Intracardiac Echocardiography in Interventional Cardiology: Working With the Anatomy Rather Than Fighting It. *Circulation* 2018, 137, 2278–2294. [CrossRef]

11. Moon, J.; Kang, W.C.; Kim, S.; Kim, M.G.; Oh, P.C.; Park, Y.M.; Chung, W.J.; Choi, D.Y.; Lee, J.Y.; Lee, Y.B.; et al. Comparison of Outcomes after Device Closure with Transseptal Puncture and Standard Technique in Patients with Patent Foramen Ovale and Ischemic Events. *J. Interv. Cardiol.* 2016, 29, 400–405. [CrossRef] [PubMed]

12. Moon, J.; Kim, M.; Oh, P.C.; Shin, D.H.; Park, H.M.; Jo, Y.Y.; Lee, J.S.; Kang, W.C. Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data. *J. Stroke. Cerebrovasc. Dis.* 2019, 28, 347–353. [CrossRef] [PubMed]

13. Mas, J.L.; Zubler, M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptographic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. *Am. Heart J.* 1995, 130, 1083–1088. [CrossRef]

14. Olivares-Reyes, A.; Chan, S.; Lazar, E.J.; Bandlamudi, K.; Narla, V.; Ong, K. Atrial septal aneurysm: A new classification in two hundred five adults. *J. Am. Soc. Echocardiogr.* 1997, 10, 644–656. [CrossRef]

15. Khositseth, A.; Cabalka, A.K.; Sweeney, J.P.; Fortuin, F.D.; Reeder, G.S.; Connolly, H.M.; Hagler, D.J. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. *Mayo Clinic Proc.* 2004, 79, 35–41. [CrossRef]

16. Thaler, D.E.; Di Angelantonio, E.; Di Tullio, M.R.; Donovan, J.S.; Griffith, J.; Homma, S.; Jaigobin, C.; Mas, J.L.; Mattle, H.P.; Michel, P.; et al. The risk of paradoxical embolism (RoPE) study: Initial description of the completed database. *Int. J. Stroke* 2013, 8, 612–619. [CrossRef]

17. Kent, D.M.; Ruthazer, R.; Weimar, C.; Mas, J.L.; Serena, J.; Homma, S.; Di Angelantonio, E.; Di Tullio, M.R.; Lutz, J.S.; Elkind, M.S.; et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. *Neurology* 2013, 81, 619–625. [CrossRef]

18. Bridges, N.D.; Hellenbrand, W.; Latson, L.; Filiano, J.; Newburger, J.W.; Lock, J.E. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. *Circulation* 1992, 86, 1902–1908. [CrossRef]

19. Alqahtani, F.; Bhirud, A.; Aljohani, S.; Mills, J.; Kawarsa, A.; Runkana, A.; Alkhouri, M. Intracardiac versus transesophageal echocardiography to guide transcatheter closure of interatrial communications: Nationwide trend and comparative analysis. *J. Interv. Cardiol.* 2017, 30, 234–241. [CrossRef]

20. Marrache, N.F.; Martin, D.O.; Wazni, O.; Gillinov, A.M.; Klein, A.; Bhargava, M.; Saad, E.; Bash, D.; Yamada, H.; Jaber, W.; et al. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: Impact on outcome and complications. *Circulation* 2003, 107, 2710–2716. [CrossRef]
21. Razminia, M.; Willoughby, M.C.; Demo, H.; Keshmiri, H.; Wang, T.; D'Silva, O.J.; Zheutlin, T.A.; Jibawi, H.; Okhumale, P.; Kehoe, R.F. Fluoroless Catheter Ablation of Cardiac Arrhythmias: A 5-Year Experience. *Pacing Clin. Electrophysiol.* **2017**, *40*, 425–433. [CrossRef] [PubMed]

22. Korsholm, K.; Jensen, J.M.; Nielsen-Kudsk, J.E. Intracardiac Echocardiography From the Left Atrium for Procedural Guidance of Transcatheter Left Atrial Appendage Occlusion. *JACC Cardiovasc. Interv.* **2017**, *10*, 2198–2206. [CrossRef] [PubMed]

23. Hijazi, Z.; Wang, Z.; Cao, Q.; Koenig, P.; Waight, D.; Lang, R. Transcatheter closure of atrial septal defects and patent foramen ovale under intracardiac echocardiographic guidance: Feasibility and comparison with transesophageal echocardiography. *Catheter. Cardiovasc. Interv.* **2001**, *52*, 194–199. [CrossRef]

24. Mullen, M.J.; Dias, B.F.; Walker, F.; Siu, S.C.; Benson, L.N.; McLaughlin, P.R. Intracardiac echocardiography guided device closure of atrial septal defects. *J. Am. Coll. Cardiol.* **2003**, *41*, 285–292. [CrossRef]

25. Vigna, C.; Marchese, N.; Zanchetta, M.; Chessa, M.; Inchingolo, V.; Pacilli, M.A.; Amico, C.; Fanelli, M.; Fanelli, R.; Loperfido, F. Echocardiographic guidance of percutaneous patent foramen ovale closure: Head-to-head comparison of transesophageal versus rotational intracardiac echocardiography. *Echocardiography* **2012**, *29*, 1103–1110. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).